Articles On Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals (NEU) opens the first site in the United States for its phase two clinical trial in Prader-Willi syndrome Neuren’s open-label, phase two trial will be conducted in up to 20 children with the condition to examine th...

Ramsay Healthcare rises after announcing it is looking to sell its joint Asian venture Neuren announces first US site for its Phase 2 clinical trial for Prader-Willi syndrome Microba starts Phase 1 clinical trial for IBD Therapeutic for u...

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

Sigma offers very competitive terms to win back Chemist Warehouse contract from Rival EBOS  Pacific Edge slumps ~60% after the US Medicare ended coverage for its Cxbladder test Avita Medical gets US FDA premarket approval for use of its RE...

Australian company Neuren Pharmaceuticals (ASX:NEU) has received the US$40 million milestone payment of US$40 million from Acadia for the US approval and first sale of its treatment for Rett syndrome.

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

The final day of the trading week saw the ASX finish in the green up 0.48 per cent. This comes after the US senate voted to suspend the country’s debt ceiling until 2025, avoiding a potentially catastrophic default. In the green U...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

A market analyst has outlined why three ASX shares are a buy in the eyes of the team at Bell Potter. The Neuren Pharmaceuticals Ltd (ASX: NEU), Gold Road Resources Ltd (ASX: GOR) and Accent Group Ltd (ASX1) share prices could all have an...

Wall Street was closed for Memorial Day, European shares were slightly down Beware of “downside correction” in the US market, expert says Rampant short-selling is putting pressure on the oil markets   Wall Street was closed for Memorial D...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

EBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest ASX biotech company to achieve a key catalyst, opening door to US$2.5 billion market Company now working on regulatory and commercialisatio...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

ASX health stocks rise in the past five days in line with broader markets Immutep  surges 46% after positive Phase 2 results into lung cancer Avita Medical falls 28% in past five days despite reporting “solid Q1 FY23” results Healthcare a...

ASX health stocks rise in the past five days outperforming broader markets Avita Medical product sales up 40% on pcp to US$10.5 million in Q1 FY23 Proteomics International Laboratories inks a deal with Sonic Healthcare USA Healthcare and...

Have you ever wondered which ASX shares rich people have bought? Maybe you’d like to emulate their portfolio? Surely if they’re wealthy then they must know what they’re doing? Well, the cat need not be killed because this week investment p...

ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor...

ASX health stocks fall 0.32% in the past five days, despite rise in broader markets Neuren Pharmaceutical announces its DAYBUE drug officially available in US to treat Rett Syndrome Impedimed quarterly results in line with expectations wit...

Australian company Neuren Pharmaceuticals (ASX:NEU) is set to receive a US$40 million milestone payment following the US launch of its treatment for Rett syndrome.

ShareCafeASX recoups some earlier losses to close 0.29% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.29 per cent lower at 7,360.20, primarily due to a 1.9 per cent decline in the energy sector, with Woodside (ASX:W...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX slumped by 0.4% today as the RBA released its April minutes Core Lithium jumped 8pc after increasing its MRE BlackRock ditched its 60/40 strategy   Local shares fell 0.4% on Tuesday after the RBA minutes revealed the central bank...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and on course to record a disappointing decline. In afternoon trade, the benchmark index is down 0.5% to 7,345.8 points. Four ASX shares that are not letting that hold them bac...

Neuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study   Market darling Neuren Pharma (ASX:NEU) jumped 4% today after announcing that DAYBUE (trofinetide) is now officially available for the trea...

The leading investors from Wilson Asset Management (WAM) have shared thoughts on two ASX shares. WAM operates several listed investment companies (LICs). Some, like WAM Leaders Ltd (ASX: WLE), focus on larger companies. Meanwhile, WAM Cap...

Investors on Stake have been turning to gold to position for market volatility as price of precious metal rises Following RBA’s rate pause Stake has seen a 150% rise in investors adding Domino’s Pizza to their watchlist Neuren Pharmaceutic...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administrat...

Healius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase 2 clinical trial in Rett Syndrome Germany allows Invex to commence the IIH EVOLVE Phase 3 clinical trial   Healius gets takeover offer fro...

Saturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jon Pilcher was despondent as he awaited news from the company’s US partner Acadia on whether the US Food and Drug Administration (FDA) had ap...

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small gain. In afternoon trade, the benchmark index is up 0.2% to 6,978.3 points. Four ASX shares that are climbing more than most today are listed below. Here’s w...

The S&P/ASX 300 index may be trading notably lower than its recent highs, but that hasn’t stopped a couple of shares on the index from climbing to record highs today. The two ASX 300 shares that have reached these milestones are list...

Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech's treatment of Rett syndrome. -Nueren share price surged by more than 50% in four days-Neuren's tronefide becomes fi...

Local shares bounced back on Wednesday following a strong rally in New York overnight Neuren was once again the best performing large cap today Former PM Paul Keating ashed out at the AUKUS deal   The ASX 200 bounced back on Wednesday as...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) on course for a much-needed gain. At the time of writing, the benchmark index is up 0.3% to 7,029.4 points. Four ASX shares that are climbing more than most today are listed below....

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday. In morning trade, the biotech company’s shares are up a further 14% to a multi-year high of $11.36. This means the ASX 300 share has now risen a w...

ASX hammered as bank-driven fear grips the market like a python round a possum XEC Emerging Companies falls more than 2.0% because they’re young and don’t know any better Safe haven goldies still managed to make bank. Sorry… poor choice of...

The ASX fell 1.6% on Tuesday on concerns of a global meltdown following SVB’s collapse Gold stocks and Bitcoin gained as Treasury yields collapsed Goldman Sachs now expects the Fed to keep rates on hold this month   The ASX 200 fell 1.6%...

The S&P/ASX 200 Index (ASX: XJO) is out of form again on Tuesday. In afternoon trade, the benchmark index is down 1.65% to 6,992.1 points. Four ASX shares that are not letting that hold them back today are listed below. Here’s why th...

A major win for Australian company Neuren Pharmaceuticals (ASX:NEU) with the US FDA approving its treatment for Rett syndrome.

ASX weathers a US bank collapse storm to finish the day down just 0.5% XEC Emerging Companies index down 0.84% because it was out partying all weekend. The Goldies take the gongs, after the precious metal jumped more than 1.0%   Looking a...

ShareCafeTech and Financials drag ASX 0.5% lower at the close by Peter Milios   On Monday, the S&P/ASX 200 decreased by 0.5 per cent, or 35.9 points, to 7108.8 due to losses in the financials and technology sectors. Gold miners performe...

13 Mar 2023 - A snapshot of the stocks on the move featuring Neuren Pharmaceuticals (ASX:NEU), Metro Mining (ASX:MMI) and Meteoric Resources (ASX:MEI).

The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. At the time of writing, the benchmark index is off its lows but down 0.2% to 7,130.1 points. Four ASX shares that are not letting that hold them back today ar...

ShareCafeASX down 0.61% at noon as SVB saga continues by Peter Milios   The collapse of Silicon Valley Bank has caused concern in the US banking and technology industries, reminding investors of the risks they had ignored. Bank stocks have...

ShareCafeStocks of the Hour: NEU, MMI, MEI                    Neuren Pharmaceuticals (ASX:NEU) has announced that they have received an FDA approval for their DAYBUE product, which is the first approved treatment for Rett syndrome. In...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Melbourne-based Neuren Pharmaceuticals (ASX: NEU) has announced that its North American partner Acadia Pharmaceuticals (NASDAQ: ACAD) has received US Food and Drug Adm...

Neuren Pharma gets a ‘historic’ FDA approval for DAYBUE to treat Rett syndrome Genetic Technologies published another research paper HITIQ sells 200 Nexus Head Impact Sensors to Monash University   Neuren Pharmaceuticals (ASX:NEU) surged...